HASBROUCK HEIGHTS, N.J., October 24 /CNW/ - Nymox Pharmaceutical Corporation (NASDAQ: NYMX - News) today announced that clinical trial data from the Company’s long term studies of NX-1207 for benign prostatic hyperplasia (BPH) will be presented at the Western Section of the American Urological Association Meeting in Scottsdale, Arizona next week on October 30. The paper is authored by leading clinical research investigators participating in the U.S. clinical trials of NX-1207.
